Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company headquartered in Suzhou, China, has announced its Initial Public Offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). Latham & Watkins advised the Joint Sponsors Goldman Sachs and China International Capital Corporation Hong Kong Securities Limited in the transaction. As Transcenta is currently in the pre-revenue stage, the listing was conducted under Chapter 18A of the HKEX guidance regarding listings of biotech companies that are unable to satisfy the profit test or market capitalization/revenue/cash flow test. Transcenta’s offering consisted of 40,330,000 shares valued at...